For readers who might not be familiar with Teva, the company became the world's largest producer of generic drugs and the undisputed national hi tech champion of Israel. Unlike so many of the vaunted Israeli start-ups that have gone from creation to exit in less than a decade, leaving their founders with millions, if not hundreds of millions of dollars, but adding little to the overall macro-employment situation in Israel, Teva maintained (either organically or by acquisition) multiple plants in Israel, as well as keeping the company an Israeli entity with its headquarters in a suburb of Tel-Aviv. Yet, on December 14th, the company (with a new CEO, Kåre Schultz, formerly of Novo Nordisk) announced that it would eliminate a quarter of its employees world-wide, including 1,700 in Israel.
This number may not seem like the cause for national economic mourning, but in the Israeli context, there is no other way to describe the impact of the cut-backs on the national psyche. The New York Times (" 'Nobody Thought It Would Come to This': Drug Maker Teva Faces a Crisis", December 17, 2017) described Teva as the "corporate version of a national celebrity", the one genuine instance of a home-grown company that became a world leader in its field. Indeed, there are few pension funds in the country that do not hold Teva stock, such that it became, again, in the words of The New York Times, "the people's stock".
It is the company’s long-time roots in the country that strike a particular chord, dating back to the early 20th century, when the predecessor to what is now Teva began to distribute--via camels and donkeys-- drugs and like products in what was then Turkish Palestine. This blogger recalls being told the story of those early days by a third-generation descendant of founders, a source of continuing family pride, but a story also recounted fondly by broader swathes of the Israeli population.
But behind this romanticism is a medium-sized pharmaceutical company, by international standards, which had everything go right for it— for a while. In the 1960's, certain national legislation enabled the company to enter the market for generic drugs and hone the management and execution skills needed to successfully compete in this market. At that time, the company was blessed with a larger-than-life chief executive, Eli Hurvitz, who drove the company's international expansion in the area of generics while continuing to keep the company Israeli-focused to the extent possible throughout his tenure at the company (he retired as CEO in 2002). This included establishing plants in the country's periphery, long a backwater in the country's economy. Further, the company enjoyed oversized success as a patent licensee (from the Weizmann Institute of Science in Israel) of the branded drug—COPAXONE, used to treat multiple sclerosis, the sales of which came to constitute nearly 40% of the company's operating profits in some years.
Second, the company is facing a patent cliff regarding the COPAXONE product: the brand name is not likely to be of commercial consequence post-patent as competitors enter with lower-cost alternatives. Teva thereby faces the double whammy of not having a proprietary block-buster product to replace COPAXONE plus a declining competitive position in the generic market.
Third, the company's declining fortunes in the generic drug area was exacerbated as a result of its acquisition in 2015 of the Actavis generic products division from Allergen. The purchase price was $40.5 billion. Debate in the Israeli business press has raged over whether Teva overpaid at the time, given the state of the generics market, or whether the wisdom of hindsight rules. Whatever is correct, the company has $35 billion in debt and is facing a cash squeeze. Cutting costs is the only short-term strategy. The announced restructuring is expected to save the company $3 billion by 2019.
This blogger previously discussed ("When a company's future is caught in the generic drug/proprietary drug crosshairs") the particular challenge of a pharmaceutical company of the size of Teva, with 2016 revenues in the amount of $21.9 billion, and a market capitalization that has declined nearly $20 billion during 2017. How to right the ship with respect to its generic products, while also ramping up the necessary R&D to support a viable proprietary drug business, is daunting for even the largest pharmaceutical company. However Teva responds to this challenge, it is difficult to imagine that it will keep its status within Israel as the undisputed national industrial champion. There is no one else to replace it.
By Neil Wilkof